Memphasys (ASX:MEM) Market Cap: A$19.93 Mil (As of Jun. 26, 2026)


What is Memphasys Market Cap?

Memphasys ASX:MEM Market Cap is A$19.93 Mil as of Jun. 26, 2026. The stock has 5 warning signs investors should review. Among 866 Medical Devices & Instruments companies, Memphasys ranks worse than 81.99% on this metric.

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Memphasys's share price for the quarter that ended in Dec. 2025 was A$0.007. Memphasys's Shares Outstanding (EOP) for the quarter that ended in Dec. 2025 was 2,687.20 Mil. Therefore, Memphasys's market cap for the quarter that ended in Dec. 2025 was A$18.81 Mil.

Memphasys's quarterly market cap declined from Dec. 2024 (A$14.17 Mil) to Jun. 2025 (A$7.93 Mil) but then increased from Jun. 2025 (A$7.93 Mil) to Dec. 2025 (A$18.81 Mil).

Memphasys's annual market cap declined from Jun. 2023 (A$13.43 Mil) to Jun. 2024 (A$9.68 Mil) and declined from Jun. 2024 (A$9.68 Mil) to Jun. 2025 (A$7.93 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Memphasys's Enterprise Value for Today is A$23.89 Mil.


Memphasys  (ASX:MEM) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the company’s debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.


Memphasys Market Cap Related Terms


Memphasys Market Cap Historical Data

* Premium members only.

The historical data trend for Memphasys's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Memphasys Market Cap Chart

Memphasys Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Market Cap
Get a 7-Day Free Trial Premium Member Only Premium Member Only 48.63 31.69 13.43 9.68 7.93

Memphasys Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Market Cap Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.57 9.68 14.17 7.93 18.81

ASX:MEM vs ABT, SYK, MDT: Market Cap Comparison

For the Medical Devices subindustry, Memphasys's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Memphasys Market Cap vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Memphasys's Market Cap distribution charts can be found below:

* The bar in red indicates where Memphasys's Market Cap falls into.



Memphasys Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

Memphasys's Market Cap for the fiscal year that ended in Jun. 2025 is calculated as

Market Cap (A: Jun. 2025 )=Share Price (A: Jun. 2025 )*Shares Outstanding (EOP) (A: Jun. 2025 )
=A$0.003857*2057.065
=A$7.93

Memphasys's Market Cap for the quarter that ended in Dec. 2025 is calculated as

Market Cap (Q: Dec. 2025 )=Share Price (Q: Dec. 2025 )*Shares Outstanding (EOP) (Q: Dec. 2025 )
=A$0.007*2687.201
=A$18.81

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Market Cap →
What does a Market Cap of A$19.93 Mil mean?
Memphasys (ASX:MEM) has a Market Cap of A$19.93 Mil as of Jun. 26, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Memphasys and its competitors. According to the industry distribution chart, Memphasys ranks #710 out of 866 companies in the Medical Devices & Instruments industry, placing it in the top 82%.
Is Memphasys' Market Cap too high?
Memphasys' current Market Cap is A$19.93 Mil. Based on the distribution chart, Memphasys ranks #710 out of 866 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers.
How does Memphasys' Market Cap compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Memphasys ranks #710 out of 866 companies for Market Cap. This places Memphasys in the lower half of its industry. The industry median Market Cap is 121.29. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Medical Devices & Instruments company?
The median Market Cap among Medical Devices & Instruments companies is 121.29, based on 866 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Memphasys and its competitors. For the Medical Devices & Instruments industry, the median Market Cap is 121.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Memphasys's current Market Cap is A$19.93 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Memphasys stock overvalued right now?
Memphasys (ASX:MEM) has a current Market Cap of A$19.93 Mil. The current Market Cap is A$19.93 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Memphasys (ASX:MEM), the current Market Cap is A$19.93 Mil as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Memphasys Business Description

Other Exchanges IG7:Germany
Address 34-36 Richmond Road, Level 1, Homebush West, Sydney, NSW, AUS, 2140
Memphasys Ltd is an Australian reproductive biotechnology company developing and commercializing novel reproduction and fertility solutions for humans and animals. The products in its development pipeline include a range of devices, media, and in vitro diagnostic solutions. The company is currently focused on the commercialisation of its patented Felix System, a novel bio-separation technology for assisted reproduction, designed to revolutionise sperm separation in assisted reproductive technology (ART) by providing a rapid, gentle, and automated process. The group has only one operating segment, being Reproductive Technologies, the assets and liabilities of which are located in Australia.